Stocklytics Platform
Asset logo for symbol DNLI
Denali Therapeutics
DNLI44
$14.85arrow_drop_up1.78%$0.25
Asset logo for symbol DNLI
DNLI44

$14.85

arrow_drop_up1.78%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Denali Therapeutics (DNLI) Stocklytics Forecast

The stock price of Denali Therapeutics Inc (DNLI) is subject to various predictions and forecasts. Analysts and experts utilize different methodologies and models to estimate the future performance of DNLI stock. One prediction suggests that the stock price of DNLI will experience significant growth in the coming years. This forecast is based on the company's strong pipeline and advancements in the field of therapeutic development. With the continuous progress in their research and development efforts, DNLI is expected to achieve positive results, which will positively impact its stock price.
Machine learning algorithms also play a role in predicting the stock price of DNLI. By analyzing historical data and market trends, these algorithms can identify patterns and make predictions about future price movements. AI-powered models for DNLI stock price prediction indicate that the stock has the potential to outperform the market and generate significant returns for investors. These predictions are based on various factors such as the company's financial health, technological advancements, and market demand for its products and services.
add Denali Therapeutics  to watchlist

Keep an eye on Denali Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Denali Therapeutics (DNLI) stock?

Analysts have set a target price of $61.32 for Denali Therapeutics (DNLI), based on forecasts from 25 analysts. The predicted price range extends from a high of $105 to a low of $22. This represents a potential increase of up to 607.07% and a decrease of 48.15% from the current price of $14.85. These forecasts are as of 2023 Feb 28.
help

What are the analyst ratings for Denali Therapeutics (DNLI) stock?

The analyst ratings for Denali Therapeutics (DNLI) are distributed as follows: 18 analysts recommend buying, 1 have a neutral stance, and 0 suggest selling. The prevailing sentiment among the total of 19 analysts leans towards a buy rating. These ratings indicate the general sentiment among the analysts covering Denali Therapeutics .
help

What is the AI price prediction for Denali Therapeutics (DNLI) stock?

At present, there is no AI or machine-learning-based price prediction available for Denali Therapeutics (DNLI) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level